2,168.00 
34.00(1.59%) 11:39AM EDT
| Prev Close: | 2,134.00 |
|---|
| Open: | 2,139.00 |
|---|
| Bid: | 2,167.00 |
|---|
| Ask: | 2,169.00 |
|---|
| 1y Target Est: | 35.61 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2,132.00 - 2,174.00 |
|---|
| 52wk Range: | 1,682.00 - 2,174.00 |
|---|
| Volume: | 1,907,272 |
|---|
| Avg Vol (3m): | 1,862,170 |
|---|
| Market Cap: | 11.96B |
|---|
| P/E (ttm): | 2,125.49 |
|---|
| EPS (ttm): | 1.02 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in GBp.
Headlines
- UK Stocks-Factors to watch on May 21at Reuters(Tue, May 21)
- Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic DiseasesPR Newswire(Mon, May 20)
- Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual MeetingPR Newswire(Fri, May 17)
- 3 FTSE 100 Shares the Market Loves: Rio Tinto, Shire, and Experianat Motley Fool(Wed, May 15)
- U.K. Stocks Extend Five-Year High as BT Climbs on Profitat Bloomberg(Fri, May 10)
- Shire Wins Block of Actavis’s Lialda Copy Until 2020at Bloomberg(Thu, May 9)
- Shire Wins Patent Trial Against Watson Concerning LIALDA®PR Newswire(Thu, May 9)
- BRIEF-Shire wins patent trial against Watsonat Reuters(Thu, May 9)
- Shire slumps after lowering revenue outlookAP(Thu, May 2)
- ADR REPORT-ECB rate cut, jobless claims data lift ADRsat Reuters(Thu, May 2)
- U.K. stocks end higher after ECB rate cutat MarketWatch(Thu, May 2)
- UPDATE 1-Shire cuts sales forecast as some drugs miss Q1 targetsat Reuters(Thu, May 2)
- BRIEF-Shire's Ornskov says will refocus on late-stage pipelineat Reuters(Thu, May 2)
- Shire Cuts Full-Year Sales Forecast as Revenue Misses Estimatesat Bloomberg(Thu, May 2)
- Shire delivers Q1 earnings beat on strong product salesat Reuters(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | 8.64 |
|---|
| P/S (ttm): | 251.94 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.21 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.56 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 1.53 |
|---|
Business Summary
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products.
View More